Precision medicine in colorectal cancer: the molecular profile alters treatment strategies

Therapeutic Advances in Medical Oncology
Nguyen H TranDustin A Deming

Abstract

When considering treatment options for patients with metastatic colorectal cancer (mCRC), molecular profiling has become a pivotal component in guiding clinical decisions. FOLFOX and FOLFIRI (fluorouracuil, leucovorin plus oxaliplatin or ininotecan, respectively) are the standard base regimens used for the treatment of mCRC. Biologic agents, such as the epidermal growth factor receptor (EGFR) targeted therapies, cetuximab and panitumumab and the vascular endothelial growth factor monoclonal antibody, bevacizumab, are safe and effective in the first-line setting. The most efficacious use of these agents in terms of timing and selection of the right patient population continues to be debated. Here we review multiple investigations into the effectiveness of treatment options as a function of the mutations present in colon cancers. Early studies have reported that KRAS mutations at exon 2 predict resistance to EGFR targeted therapies. More recently the data have expanded to include KRAS mutations at exons 3 and 4 and NRAS mutations at exons 2, 3 and 4 as well as other biomarkers including BRAF and PIK3CA, leading to the evolution of the treatment of mCRC to a more precision-based approach. As our understanding of relevant biomarker...Continue Reading

References

Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A de GramontA Bonetti
Sep 28, 2000·The New England Journal of Medicine·L B SaltzL L Miller
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Mar 16, 2004·Science·Yardena SamuelsVictor E Velculescu
Jul 19, 2005·Cancer Research·Wade S SamowitzMartha L Slattery
Apr 19, 2006·Cancer Research·Astrid LièvrePierre Laurent-Puig
Oct 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles S FuchsJosé Barrueco
Jan 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Astrid LièvrePierre Laurent-Puig
Jan 29, 2008·International Journal of Cancer. Journal International Du Cancer·Ludovic BaraultFrancoise Piard
Aug 2, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F PerroneS Pilotti
Sep 20, 2008·Virchows Archiv : an International Journal of Pathology·J H J M van KriekenA Ensari
Nov 13, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Federica Di NicolantonioAlberto Bardelli
Apr 3, 2009·The New England Journal of Medicine·Eric Van CutsemPhilippe Rougier
Apr 16, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hans PrenenSabine Tejpar
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Susan D RichmanPhilip Quirke
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre Laurent-PuigFrédérique Penault-Llorca
Jan 14, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C BokemeyerP Koralewski
Mar 27, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Carsten BokemeyerClaus-Henning Köhne
Apr 5, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kjell Magne TveitThoralf Christoffersen
Sep 13, 2013·The New England Journal of Medicine·Jean-Yves DouillardScott D Patterson
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Jan 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemFortunato Ciardiello

❮ Previous
Next ❯

Citations

May 9, 2016·The Journal of Allergy and Clinical Immunology·Chrysanthi SkevakiCatherine A Thornton
Jul 17, 2016·Drug Discovery Today·Aleksander SkardalAnthony Atala
Sep 4, 2016·Seminars in Cell & Developmental Biology·Jiayun HouZhitu Zhu
Oct 30, 2016·Trends in Pharmacological Sciences·Nicholas C Dracopoli, Mark S Boguski
Mar 8, 2017·Journal of Biomolecular Structure & Dynamics·Mahalakshmi RVijayalakshmi Mahadevan
Nov 15, 2016·Journal of Inorganic Biochemistry·Cristina Sánchez-de-DiegoElena Cerrada
Mar 18, 2016·Journal of Cell Science·G Aaron HobbsKent L Rossman
Jan 20, 2019·Journal of Clinical Medicine·Joon-Hyop LeeHeejoon Chae
Feb 15, 2018·Scientific Reports·Andrea R MazzocchiAleksander Skardal
Mar 7, 2018·Oncotarget·Klaus Højgaard JensenFlemming Brandt Sørensen
Dec 16, 2018·BMC Medical Informatics and Decision Making·Ellen G EngelhardtVeerle M H Coupé
Dec 28, 2018·Cancers·Marta Tellez-GabrielDominique Heymann
Sep 9, 2017·Advanced Healthcare Materials·Joseph ParkHansang Cho
Nov 15, 2018·Molecular Cancer Therapeutics·Stephanie L FrickeDustin A Deming
Dec 17, 2020·Journal of Personalized Medicine·Hossein TaghizadehGerald W Prager
Feb 24, 2021·Healthcare Management Forum·Larry ArshoffDavid Kinniburgh
Mar 12, 2021·Cell Communication and Signaling : CCS·Camille Ternet, Christina Kiel

❮ Previous
Next ❯

Software Mentioned

PRIME

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.